Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children Aged 12 to 23 Months
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Journal of Infectious Diseases
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age
J. Infect. Dis 2023 May 29;227(11)1293-1302, J Díez-Domingo, X Sáez-Llorens, MA Rodriguez-Weber, C Epalza, A Chatterjee, CH Chiu, CY Lin, AA Berry, F Martinón-Torres, F Baquero-Artigao, JM Langley, JT Ramos Amador, JB Domachowske, LM Huang, NC Chiu, S Esposito, P Moris, T Lien-Anh Nguyen, V Nikic, W Woo, Y Zhou, I Dieussaert, A Leach, A Gonzalez Lopez, N VanhoutteFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.